Allergic eosinophilic esophagitis drives dysregulated innate immunity in esophageal fibroblasts

Active Grant Awarded

Award ID
R01AI202280
Recipient
Awarding agency
Obligated
$1,496,677

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 7% complete
Place of performance
La Jolla, CA 92093, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded University of California, San Diego (doing business as UC San Diego Health) an obligated $1.496677 million on July 21, 2026, under Grant R01AI202280. The award falls under the Allergy and Infectious Diseases Research program (CFDA 93.855), which funds biomedical research and research training in infectious, immunologic, and allergic diseases. The period of performance runs through June 30, 2031, with work performed in La Jolla, California 92093.

The project tests whether allergic inflammation drives chronic innate immune activation of esophageal fibroblasts in eosinophilic esophagitis, with primary investigator Seema Aceves, MD, PhD. It builds on single-cell sequencing and functional analysis showing inflammation-associated fibroblasts that express CD14 and respond to CD14-TLR4 ligation, and on spatial studies placing these fibroblasts near immune cells. Four sub-recipients perform defined work under the award, with subaward dates from August 3 to September 22, 2026:

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Division of Gastroenterology, Hepatology and Nutrition (investigator Joshua B. Wechsler, MD, MS), studies CD14's role in promoting fibroblast function.
  • University of North Carolina at Chapel Hill, where co-investigator Evan Dellon, MD, identifies existing biosamples in EoE clinical trial biobanks and registries, enrolls new patients when needed, and oversees regulatory and human subjects aspects at the site.
  • La Jolla Institute for Immunology, Ay lab, performs epigenetic analysis of patient-derived cell lines using ATAC-seq and Hi-C, conducts computational integration, and shares datasets through dbGaP and GEO/SRA.
  • The Leland Stanford Junior University, Nolan lab, processes 66 samples by CODEX multiplex imaging with an estimated 64 concurrent antibodies and builds a cellular neighborhood map of normal and EoE esophagus.

Description

Abstract
Eosinophilic esophagitis (EOE) is a chronic food antigen driven type 2 inflammatory disease that requires repeated endoscopy with tissue biopsy for diagnosis and management. Chronic EOE leads to tissue fibrosis with resultant esophageal rigidity, strictures, food impactions, and failure to thrive. Before EOE, no other allergic disease lent itself to understanding remodeling longitudinally at the human tissue level. Delayed diagnosis, inconsistent clinical follow-up, non-adherence, non-response, or discontinuation of therapy, and eosinophil recurrence despite therapy are all common clinical scenarios; each increases the risk of strictures. Tissue remodeling begins in childhood, but we have no prediction or severity stratification models. Fibrosis is challenging, and sometimes impossible, to treat. Our inability to uniformly alter fibrosis is due to a critical knowledge GAP in understanding pathogenic EOE fibroblast phenotypes and functions. Deepening our understanding of the mechanisms driving the development, retention, and activation of pathogenic inflammation associated fibroblasts (IAFS) and delineating their tissue spatial interactions with other cells is imperative. We have demonstrated that EOE IAFS retain transcriptional and proteomic memory of exposure to in vivo inflammation. Our new data based on single cell sequence and functional analysis of primary esophageal fibroblasts show EOE IAFS display a pro-inflammatory and interferon-stimulated gene response signature. A subset of IAFS express cell-surface CD14 and respond to CD14-TLR4 ligation with induced IAF and interferon gene expression. Spatial studies show that EOE IAFS reside near immune cells. We propose the novel central hypothesis that allergic inflammation drives chronic innate immune activation of fibroblasts and that the retention of IAF-rich spatial neighborhoods aligns with EOE severity and recidivism. We aim to define the spatial cell neighborhoods containing IAFS longitudinally and by severity with cutting edge multiplex spatial imaging (CODEX) and samples sourced during routine care and clinical trials. We will determine the immune mechanisms that perpetuate IAFS and their innate immune activation with a focus on how CD14-TLR4 ligation can immuno-program fibroblasts toward pathogenesis. CODEX integrated with single cell RNA sequence of biopsy fibroblasts will create an unparalleled view of tissue fibroblast phenotypes and dysfunctions over time and by biogeography in a chronic allergic disease. Primary esophageal fibroblasts isolated longitudinally from the same patient during active and remission EOE will be used to dissect the mechanisms underlying the retention of IAF transcriptomes. All studies will be contextualized to patient severity and clinical trajectory as defined by objective clinical measures. With our well phenotyped cohort of patients and a team of experts in translational EOE (aceves, dellon, wechsler), innate immunity (ULEVITCH), and computational analyses (nolan, AY), the totality of the work proposed here will lead to a deep understanding of disease pathogenesis and define innovative approaches to measure disease severity and clinical course and point to novel therapeutic modalities.

Subawards

Subrecipient Amount Awarded
ANN & Robert H Lurie Childrens Hospital Of Chicago Sub:76,844.00 09/22/2026 Statement of Work for: Allergic eosinophilic esophagitis drives dysregulated innate immunity in esophageal fibroblasts R01 subaward… $76,844
University Of North Carolina At Chapel Hill Sub: 58,935.00 08/24/2026 SCOPE OF WORK For this R01 application, UNC will be a study site with a subcontract with University of California, San Diego (UCSD).… $58,935
La Jolla Institute For Immunology Sub: 148,800.00 08/11/2026 STATEMENT OF WORK Dr. Ay and his lab will be responsible for the epigenetic analysis of patient-derived cell lines. This includes… $148,800
The Leland Stanford Junior University Sub: 385,000.00 08/03/2026 The Nolan lab will process and analyze 66 samples using CODEX multiplex imaging with an estimated use of 64 concurrent antibodies.… $385,000

Quick answers

Who received award R01AI202280?

R01AI202280 was awarded to University Of California, San Diego by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 21, 2026.

How much is award R01AI202280 worth?

$1,496,677 has been obligated on R01AI202280.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award